NCT02529995 - Phase I, Study in Chinese NSCLC Patients | Biotech Hunter

Enrollment

31

Participants

Timeline

Start Date

August 24, 2015

Primary Completion Date

January 28, 2016

Study Completion Date

September 27, 2019

Conditions

Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive

Interventions

DRUG

AZD9291 40 mg

This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).

DRUG

AZD9291 80 mg

This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).

Trial Locations (2)

200032

Research Site, Shanghai

510060

Research Site, Guangzhou